James, N., Lee, N. & Horton, R. Announcing the Lancet commission on prostate cancer comment. Lancet 397, 1865–1866 (2021).

Article  PubMed  Google Scholar 

Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).

Article  PubMed  Google Scholar 

Zoubeidi, A. & Ghosh, P. M. Celebrating the 80th anniversary of hormone ablation for prostate cancer. Endocr. Relat. Cancer 28, T1–T10 (2021).

Article  PubMed  Google Scholar 

Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701–711 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gonthier, K., Poluri, R. T. K. & Audet-Walsh, É. Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer. J. Steroid Biochem. Mol. Biol. 191, 105367 (2019).

Article  CAS  PubMed  Google Scholar 

Gonthier, K., Poluri, R. T. K., Weidmann, C., Tadros, M. & Audet-Walsh, É. Reprogramming of isocitrate dehydrogenases expression and activity by the androgen receptor in prostate cancer. Mol. Cancer Res. 17, 1699–1709 (2019).

Article  CAS  PubMed  Google Scholar 

Audet-Walsh, É. et al. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer. Genes Dev. 31, 1228–1242 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cornford, P. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer. Part II. 2020 update: treatment of relapsing and metastatic prostate cancer. Eur. Urol. 79, 263–282 (2021).

Article  CAS  PubMed  Google Scholar 

Wang, M. C. et al. Prostate antigen — a new potential marker for prostatic cancer. Prostate 2, 89–96 (1981).

Article  CAS  PubMed  Google Scholar 

Stamey, T. A. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909–916 (1987).

Article  CAS  PubMed  Google Scholar 

Stephan, C., Jung, K., Lein, M. & Diamandis, E. P. PSA and other tissue kallikreins for prostate cancer detection. Eur. J. Cancer 43, 1918–1926 (2007).

Article  CAS  PubMed  Google Scholar 

Kim, J. & Coetzee, G. A. Prostate specific antigen gene regulation by androgen receptor. J. Cell Biochem. 93, 233–241 (2004).

Article  CAS  PubMed  Google Scholar 

Wyatt, A. W. & Gleave, M. E. Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol. Med. 7, 878–894 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang, J., Lin, B. & Li, B. Anti-androgen receptor therapies in prostate cancer: a brief update and perspective. Front. Oncol. 12, 865350 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Mottet, N. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 79, 243–262 (2021).

Article  CAS  PubMed  Google Scholar 

Jamroze, A., Chatta, G. & Tang, D. G. Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance. Cancer Lett. 518, 1–9 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharifi, N. & Auchus, R. J. Steroid biosynthesis and prostate cancer. Steroids 77, 719–726 (2012).

Article  CAS  PubMed  Google Scholar 

Labrie, F., Dupont, A., Simard, J., Luuthe, V. & Belanger, A. Intracrinology — the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur. Urol. 24, 94–105 (1993).

Article  PubMed  Google Scholar 

Litwin, M. S. & Tan, H. J. The diagnosis and treatment of prostate cancer a review. J. Am. Med. Assoc. 317, 2532–2542 (2017).

Article  Google Scholar 

Klotz, L. et al. Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Can. Urol. Assoc. J. 11, 16–23 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Chi, K. et al. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann. Oncol. 26, 2044–2056 (2015).

Article  CAS  PubMed  Google Scholar 

Harris, W. P., Mostaghel, E. A., Nelson, P. S. & Montgomery, B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat. Clin. Pract. Urol. 6, 76–85 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bolla, M. et al. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360, 2516–2527 (2009).

Article  CAS  PubMed  Google Scholar 

Gillessen, S. et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur. Urol. 73, 178–211 (2018).

Article  PubMed  Google Scholar 

Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).

Article  CAS  PubMed  Google Scholar 

James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377, 338–351 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377, 352–360 (2017).

Article  CAS  PubMed  Google Scholar 

De Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Marchetti, P. M. & Barth, J. H. Clinical biochemistry of dihydrotestosterone. Ann. Clin. Biochem. 50, 95–107 (2013).

Article  CAS  PubMed  Google Scholar 

Massie, C. E. et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 30, 2719–2733 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swinnen, J. V., Ulrix, W., Heyns, W. & Verhoeven, G. Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc. Natl Acad. Sci. USA 94, 12975–12980 (1997).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Audet-Walsh, É. et al. Androgen-dependent repression of ERRγ reprograms metabolism in prostate cancer. Cancer Res. 77, 378–389 (2017).

Article  CAS  PubMed  Google Scholar 

Tennakoon, J. B. et al. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch. Oncogene 33, 5251–5261 (2014).

Article  CAS  PubMed  Google Scholar 

Bader, D. A. et al. Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat. Metab. 1, 70–85 (2019).

Article  CAS  PubMed  Google Scholar 

Huggins, C. & Hodges, C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293–297 (1941).

CAS  Google Scholar 

Kluth, L. A. et al. The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World J. Urol. 32, 669–676 (2014).

Article  CAS  PubMed  Google Scholar 

Hauger, R. L., Saelzler, U. G., Pagadala, M. S. & Panizzon, M. S. The role of testosterone, the androgen receptor, and hypothalamic-pituitary-gonadal axis in depression in ageing men. Rev. Endocr. Metab. Disord. https://doi.org/10.1007/s11154-022-09767-0.

Labrie, F. Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat. Rev. Urol. 8, 73–85 (2011).

Article  CAS  PubMed  Google Scholar 

Corti, M., Lorenzetti, S., Ubaldi, A., Zilli, R. & Marcoccia, D. Endocrine disruptors and prostate cancer. Int. J. Mol. Sci. https://doi.org/10.3390/ijms23031216 (2022).

Article